Fox Foundation Has Funded $3 Billion in Parkinson's Research
The nonprofit has accelerated drug development and clinical testing for patients across the United States.
Updated on Sept. 28, 2026 in Alzheimer’s
Live Poll
Should medical research be primarily driven by private philanthropic foundations rather than federal government investment?
The Michael J. Fox Foundation for Parkinson's Research has reached a major milestone by providing $3 billion in funding toward disease research. This investment has bolstered the current clinical landscape, where 175 therapies are now being tested.
Why it matters
The foundation was established to accelerate scientific progress, directly impacting the pipeline of new treatments for patients living with the condition. These efforts complement recent policy shifts like the National Plan to End Parkinson's Act, which became law in July 2024.
The foundation reports $3 billion in total research funding, contributing to 23 new drug approvals over the past decade. Currently, there are 175 therapies in clinical testing, though the final success rate of these trials is still under investigation.
The players
Michael J. Fox
An actor and advocate who has lived with Parkinson's disease since his diagnosis at age 29.
The Michael J. Fox Foundation for Parkinson's Research
A prominent non-profit organization focused on accelerating drug development and finding a cure for Parkinson's disease.
The details
The foundation supports scientific discovery by funding research, connecting patients with scientists, and facilitating clinical applications. Through the Parkinson's Progression Markers Initiative, researchers study disease biology to identify specific markers that can guide the development of new treatments. This systemic approach aims to bridge the gap between early laboratory discovery and usable clinical tools.
Timeline
Michael J. Fox was diagnosed with Parkinson's disease in 1991.
The foundation was established in 2000.
The National Plan to End Parkinson's Act became law in July 2024.
Michael J. Fox received the Lasker-Bloomberg Public Service Award in September 2026.
Health Landscape
The foundation's funding effort operates alongside federal frameworks like the National Plan to End Parkinson's Act, which became law in July 2024. Together, these efforts mark a shift toward more coordinated, large-scale investment in the development of neurodegenerative disease therapies.
As new therapies move through clinical testing, it is worth discussing the current state of treatment options and clinical trial eligibility with your neurologist. Staying informed about the 175 therapies currently in development can help you and your physician make better-informed care decisions.
The takeaway
The sustained increase in clinical testing highlights the importance of patient participation in research initiatives. Consider speaking with your physician about how ongoing advancements may eventually influence your specific treatment plan or symptom management strategies.
Further reading
For more context on navigating care and treatment options, visit our Alzheimer’s section.
Live Poll
Should medical research be primarily driven by private philanthropic foundations rather than federal government investment?
